FDA Greenlights AUVELITY: First New Treatment for Alzheimer’s Agitation in Years
FDA approves AUVELITY to treat Alzheimer’s agitation, offering a safer, effective option to reduce distress and improve patient care.
/ 2 items
FDA approves AUVELITY to treat Alzheimer’s agitation, offering a safer, effective option to reduce distress and improve patient care.
Axsome's AXS-05 gets FDA priority review for treating agitation in Alzheimer's patients, with decision expected by April 2026.